When was Odin Vision founded?

Odin Vision was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Odin Vision located?

Odin Vision is headquartered in London, United Kingdom.

Which legal entities is Odin Vision associated with?

Odin Vision is associated with Odin Medical Ltd.

How many employees does Odin Vision have?

As of Sep 30, 2021, the latest employee count at Odin Vision is 12.

Is Odin Vision a funded company?

Odin Vision is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jan 12, 2019.

When was the latest funding round of Odin Vision?

Odin Vision's latest funding was a $***** Seed round on May 01, 2019, with participation from 2 investors. Its primary sector is Genomics. Globally, the Genomics sector has seen $517M in funding in 2026 to date.

Where does Odin Vision rank among its competitors?

Odin Vision ranks 115th amongst 400 active competitors, of which 128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Caris Life Sciences, which secured $168M in Apr, 2025.

Who are the top competitors of Odin Vision?

Odin Vision's top competitors include Juno Therapeutics, Personalis and Caris Life Sciences. Among them, Caris Life Sciences secured the most recent funding round in April, 2025.

Odin Vision - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Odin Vision is developing AI-based applications for endoscopic procedures. The company is developing a colon cancer detection platform using deep learning technology. The platform will analyze the images taken by the endoscopic camera during polyps assessment.

Website: odin-vision.com/en_gb/
Social
Email ID: *****@odin-vision.com

Key Metrics

Founded Year

2019

Location

London, United Kingdom

Stage

Acquired

Latest Funding Round

Seed, May 01, 2019, $*****

Investors

London Co-Investment Fund & 18 more

Ranked

115^th among 400 active competitors

Employee Count

12 as on Sep 30, 2021

Similar Companies

Innovaccer & 2855 more

Exit Details

Acquired by Olympus (Dec 20, 2022)

View Odin Vision's full profile

Odin Vision is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Odin Medical Ltd CIN: 11563083 , United Kingdom, Active	Aug 10, 2018	-	12 (As on Sep 30, 2021)

Odin Vision got acquired by Olympus on Dec 20, 2022.

Click here to take a look at Odin Vision's acquisition in detail

Odin Vision has raised funding over 3 rounds. Its first funding round was on Jan 12, 2019. Its latest funding round was a Seed round on May 01, 2019 for $*****. 2 investors participated in its latest round. Odin Vision has 10 institutional investors and 9 angel investors.

Here is the list of recent funding rounds of Odin Vision:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 01, 2019	7202149	Seed	4801276	2417679	4246318	8764525
May 01, 2019	3597113	Grant (prize money)	4477260	7745582	4841880	Gov & 2 more
Jan 12, 2019	9066735	Grant (prize money)	3010098	3368147	4037400	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Odin Vision's funding rounds and investors

Odin Vision's employee count trend

Odin Vision has 12 employees as of Sep 21. The total employee count is 9.0% more than what it was in Sep 20. Here is Odin Vision's employee count trend over the years:

Uncover Odin Vision's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Odin Vision include Juno Therapeutics, Personalis and Caris Life Sciences. Here is the list of Top 10 competitors of Odin Vision, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, RA Capital Management & 14 others	74/100
2nd	Personalis 2011, Menlo Park (United States), Public	Provider of genomic sequencing and diagnosis software for the healthcare industry	$87.3M	Abingworth, Lightspeed Venture Partners & 4 others	73/100
3rd	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Coatue & 19 others	72/100
4th	UniQure 1998, Amsterdam (Netherlands), Public	Developer of gene-based therapies for patients with genetic or acquired diseases	$111M	Advent Life Sciences, Foresite Capital & 11 others	70/100
5th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
6th	Castle Biosciences 2008, Friendswood (United States), Public	Provider of diagnostic devices for treating cancer	$62M	Industry Ventures, Health Quest Capital & 9 others	70/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Third Rock Ventures & 9 others	70/100
8th	Congenica 2013, Cambridge (United Kingdom), Acquired	Provider of a platform for clinical genome analytics for treating patients with genetic diseases	$81.9M	Tencent, IDO Investments & 39 others	69/100
9th	Geneoscopy 2015, St. Louis (United States), Series C	Developer of non-invasive biomarker tests for colorectal cancer	$219M	LightChain Capital, Cultivation Capital & 18 others	68/100
10th	Freenome Health 2014, United States, Series E	Provider of a deep learning platform for detecting circulating cancer-related markers	$1.35B	RA Capital Management, Perceptive Advisors ... & 65 others	66/100
115th	Odin Vision 2019, London (United Kingdom), Acquired	Provider of AI-based colon cancer detection platform	-	London Co-Investment Fund, AlbionVC & 17 others	42/100